Sanofi (SNY)
| Previous close | 53.24 |
| Open | 52.23 |
| Bid | 51.12 x 1000 |
| Ask | 53.99 x 1300 |
| Day's range | 52.15 - 52.94 |
| 52-week range | 44.76 - 55.00 |
| Volume | 5,675,917 |
| Avg. volume | 1,315,707 |
| Market cap | 133.958B |
| Beta (5Y monthly) | 0.40 |
| PE ratio (TTM) | 9.01 |
| EPS (TTM) | 5.87 |
| Earnings date | N/A |
| Forward dividend & yield | 1.93 (3.58%) |
| Ex-dividend date | 03 May 2021 |
| 1y target est | 63.88 |
- Motley Fool
How This Pharma Company Can Benefit From Its Competitors
The race is on among pharmaceutical companies to obtain approval from the U.S. Food and Drug Administration (FDA) for new products serving the atopic dermatitis (AD, otherwise known as severe and chronic eczema) market. One of those companies, Incyte (NASDAQ: INCY), is coming off successful phase 3 trials of its ruxolitinib cream, but is now facing challenges brought on by delays in FDA approval.
- GlobeNewswire
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis
European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis PARIS – June 18, 2021 - The European Commission (EC) has approved Aubagio® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS). The EC approval is based on data from the Phase 3 TERIKIDS study. The approval confirms Aubagio as the first
- Zacks
The Zacks Analyst Blog Highlights: Apple, The Home Depot, Sanofi, Applied Materials and CVS Health
The Zacks Analyst Blog Highlights: Apple, The Home Depot, Sanofi, Applied Materials and CVS Health
